医学
专家意见
髓系白血病
重症监护医学
疾病
临床试验
内科学
肿瘤科
梅德林
政治学
法学
作者
Hartmut Döhner,Elihu H. Estey,Sergio Amadori,Frederick R. Appelbaum,Thomas Büchner,Alan Kenneth Burnett,Hervé Dombret,Pierre Fenaux,David Grimwade,Richard A. Larson,Francesco Lo‐Coco,Tomoki Naoe,Dietger Niederwieser,Gert J. Ossenkoppele,Miguel Á. Sanz,Jorge Sierra,Martin S. Tallman,Bob Löwenberg,Clara D. Bloomfield
出处
期刊:Blood
[Elsevier BV]
日期:2010-01-21
卷期号:115 (3): 453-474
被引量:2953
标识
DOI:10.1182/blood-2009-07-235358
摘要
Abstract In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion–based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.
科研通智能强力驱动
Strongly Powered by AbleSci AI